Category: Anakinra

High Dose Anakinra shows promise in treating CRS

High-Dose Anakinra shows promise in treating CRS/ICANS Post CAR T-Cell Therapy

The possibility of the cutting-edge therapeutic approach known as chimeric antigen receptor (CAR) T-cell immunotherapy to treat a variety of resistant haematological malignancies has attracted attention. The serious side effects of CAR T-cell treatment continue to be of great concern. Early after CAR-T cell therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are […]
Read More